Kymera, raising $173M+, becomes the 48th biotech IPO of the year as 2020 surpasses 2019 Nia JulianAugust 21, 2020
HotSpot Therapeutics Completes $65 Million Series B Financing to Advance Pipeline of Novel Allosteric Medicines Nia JulianMay 21, 2020
Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing Nia JulianMay 20, 2020
Rallybio Completes $145 Million Series B Financing and Announces Plans to Advance Lead Product Candidate into the Clinic in 2H 2020 Nia JulianMay 19, 2020
Orionis Biosciences Debuts with Major Pharmaceutical Collaboration to Tackle Industry’s Most Challenging Protein Targets Nia JulianMarch 9, 2020
Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing Nia JulianMarch 3, 2020
Amphivena Closes $62 Million Series C Financing to Expand the Clinical Development of AMV564 into Solid Tumors and to Develop its T Cell Engagement Portfolio Nia JulianDecember 17, 2019
Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants Nia JulianNovember 18, 2019
Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting Nia JulianNovember 12, 2019
Kymera Therapeutics to Present Preclinical Data on its First-in-Class IRAK4 Degraders Demonstrating Robust Inhibition of Inflammatory Responses and Superiority to IRAK4 Kinase Inhibitors Nia JulianNovember 11, 2019
Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting Nia JulianNovember 8, 2019
Apellis Presents Positive First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week Nia JulianNovember 8, 2019
Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders Nia JulianOctober 23, 2019
Arcellx Raises $85 Million in a Series B Financing to Advance its Intelligent Cell Therapy Platform Nia JulianOctober 3, 2019
G1 Therapeutics Presents First Clinical Data on Oral SERD G1T48 Demonstrating Safety and Tolerability in Patients with Advanced Breast Cancer at ESMO 2019 Nia JulianSeptember 29, 2019
